RxDoctor Payments Data

Phuong Tran, MD

Internal Medicine · Plano, TXNPI 1710197678

Payments from drug & device makers

$15,120in general payments, 2019–2025

Across 830 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Lilly USA, LLC$791
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$14,98499%
  • Education$1371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk126$1,943
AbbVie(2 entities)101$1,370
Pfizer67$1,190
AstraZeneca48$1,057
Amgen(2 entities)55$1,006
Lilly USA, LLC58$791
Abbott22$722
Otsuka America Pharmaceutical, Inc.29$557
Takeda Pharmaceuticals U.S.A., Inc.32$516
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$487
Johnson & Johnson29$483
Boehringer Ingelheim15$328
Cleerly, Inc.4$314
GSK17$305
Abiomed5$302
Merck19$276
E.r. Squibb & Sons, L.L.C.16$266
Corium, LLC8$193
Viiv Healthcare Company8$188
Axsome Therapeutics, Inc.5$179
Idorsia Pharmaceuticals US Inc12$178
Exact Sciences9$173
Amarin Pharma, Inc.7$155
Dexcom, Inc.7$140
Biohaven Pharmaceutical Holding Company Ltd.6$131
Astellas Pharma US Inc4$131
Sanofi-aventis U.S. LLC6$115
Aytu Biopharma, Inc.7$105
Genentech USA, Inc.5$91
Kowa Pharmaceuticals America, Inc.6$86
Seqirus USA Inc5$82
Biohaven Pharmaceuticals, Inc.4$80
Supernus Pharmaceuticals, Inc.5$74
Ardelyx, Inc.3$74
Optinose US, Inc.3$72
VBI Vaccine (delaware) Inc.2$69
Noven Therapeutics, LLC4$69
Ironwood Pharmaceuticals, Inc3$69
Novartis3$67
Indivior Inc.3$64
Eisai Inc.4$62
Madrigal Pharmaceuticals2$49
Sanofi Pasteur Inc.2$42
Bayer2$39
Esperion Therapeutics, Inc.2$37
Hologic Sales And Service, LLC1$34
Coloplast1$31
Almatica Pharma LLC1$26
Heartflow, Inc.1$26
Boston Scientific1$26
Stryker1$22
Neos Therapeutics, LP1$21
Dynavax Technologies Corporation1$20
Gilead1$19
Philips North America LLC1$18
Daiichi Sankyo Inc.1$18
Cardiovascular Systems Inc.1$18
Sunovion Pharmaceuticals Inc.1$18
Nalpropion Pharmaceuticals LLC1$17
MDD US Operations, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,120 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$46,625
Medicare patients
96
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$48,982
EliquisApixaban26$22,133
MounjaroTirzepatide14$17,139
Repatha SyringeEvolocumab16$12,363
Levothyroxine Sodium59$1,094
Tamsulosin Hcl45$1,068
Gabapentin24$1,032
Estradiol30$977
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$876
Metformin Hcl ErMetformin Hcl49$603
Omeprazole30$589
Duloxetine Hcl17$553
Rosuvastatin Calcium56$467
Losartan Potassium55$456
Atorvastatin Calcium71$446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,943$48,98231 claims
PfizerEliquis$1,190$22,13326 claims
Lilly USA, LLCMounjaro$791$17,13914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →